{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Isotonic+solution&page=2", "query": { "intervention": "Isotonic solution", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Isotonic+solution&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-16T23:19:36.388Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00350298", "title": "Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clostridium Infections" ], "interventions": [ { "name": "GS-CDA1/MDX-1388", "type": "BIOLOGICAL" }, { "name": "normal saline", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MassBiologics", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2006-07-20", "completion_date": "2008-06-25", "has_results": true, "last_update_posted_date": "2021-02-09", "last_synced_at": "2026-09-16T23:19:36.388Z", "location_count": 22, "location_summary": "Los Angeles, California • Oakland, California • Newark, Delaware + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00350298" }, { "nct_id": "NCT05952804", "title": "IVIG for Infection Prevention After CAR-T-Cell Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "Immune Globulin Infusion (Human), 10% Solution", "type": "BIOLOGICAL" }, { "name": "Anti-CD19 CAR T Cells Preparation", "type": "BIOLOGICAL" }, { "name": "Saline", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Electronic Health Record Review", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2024-06-10", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-09-16T23:19:36.388Z", "location_count": 7, "location_summary": "Duarte, California • Miami, Florida • Tampa, Florida + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05952804" }, { "nct_id": "NCT01247064", "title": "Hypertonic Saline for Acute Bronchiolitis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Bronchiolitis, Viral", "Saline Solution, Hypertonic" ], "interventions": [ { "name": "Nebulized 3% saline", "type": "DRUG" }, { "name": "Nebulized 0.9% Normal Saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Months", "maximum_age": "23 Months", "sex": "ALL", "summary": "2 Months to 23 Months" }, "enrollment_count": 62, "start_date": "2010-10", "completion_date": "2011-12", "has_results": true, "last_update_posted_date": "2014-08-19", "last_synced_at": "2026-09-16T23:19:36.388Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01247064" }, { "nct_id": "NCT03446599", "title": "Hemodynamic Effects of Methylene Blue vs Hydroxocobalamin in Patients at Risk of Vasoplegia During Cardiac Surgery", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Vasoplegia", "Hypotension", "Coronary Artery Disease", "Cardiac Valve Disease" ], "interventions": [ { "name": "Hydroxocobalamin", "type": "DRUG" }, { "name": "Methylene Blue", "type": "DRUG" }, { "name": "Normal saline", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dartmouth-Hitchcock Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-11", "completion_date": "2020-06-30", "has_results": false, "last_update_posted_date": "2020-03-02", "last_synced_at": "2026-09-16T23:19:36.388Z", "location_count": 1, "location_summary": "Lebanon, New Hampshire", "locations": [ { "city": "Lebanon", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT03446599" }, { "nct_id": "NCT02660736", "title": "Bioequivalence Study of Two Albiglutide Drug Products in Healthy Adult Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Albiglutide Liquid Auto-injector", "type": "DRUG" }, { "name": "Albiglutide Lyophilized DCC Pen Injector", "type": "DRUG" }, { "name": "Placebo Liquid Auto-injector", "type": "DRUG" }, { "name": "Placebo Lyophilized DCC Pen injector", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 59, "start_date": "2016-02", "completion_date": "2016-08", "has_results": false, "last_update_posted_date": "2016-11-09", "last_synced_at": "2026-09-16T23:19:36.388Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02660736" }, { "nct_id": "NCT02031211", "title": "TNF-alpha Inhibition in CRPS: A Randomized Controlled Trial", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "CRPS", "Chronic Regional Pain Syndrome" ], "interventions": [ { "name": "Etanercept", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "17 Years", "sex": "FEMALE", "summary": "10 Years to 17 Years · Female only" }, "enrollment_count": 0, "start_date": "2014-06", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2016-10-14", "last_synced_at": "2026-09-16T23:19:36.388Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02031211" }, { "nct_id": "NCT04019834", "title": "Preoperative Regional Nerve Block for Acute and Chronic Post-Operative Pain Following Mastectomy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Breast Cancer", "Mastectomy", "Anesthesia, Local", "Narcotic Use" ], "interventions": [ { "name": "regional nerve block with local anesthesia of bupivacaine with steroid", "type": "DRUG" }, { "name": "Placebo regional nerveblock with normal saline", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 21, "start_date": "2020-07-06", "completion_date": "2021-11-25", "has_results": false, "last_update_posted_date": "2022-08-03", "last_synced_at": "2026-09-16T23:19:36.388Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04019834" }, { "nct_id": "NCT06204432", "title": "Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Long Haul COVID-19", "Post-Acute COVID-19 Syndrome", "Anosmia", "Olfaction Disorders" ], "interventions": [ { "name": "Sodium Citrate", "type": "DRUG" }, { "name": "Normal Saline", "type": "DRUG" }, { "name": "Olfactory Training Kit - \"The Olfactory Kit, by AdvancedRx\"", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2023-12-01", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2025-02-20", "last_synced_at": "2026-09-16T23:19:36.388Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06204432" }, { "nct_id": "NCT01838863", "title": "Control of Major Bleeding After Trauma Study", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Trauma", "Hemorrhagic Shock" ], "interventions": [ { "name": "Type AB plasma", "type": "BIOLOGICAL" }, { "name": "Crystalloid fluid (standard of care for resuscitation)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Denver Health and Hospital Authority", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2014-04-07", "completion_date": "2017-04-03", "has_results": true, "last_update_posted_date": "2019-01-08", "last_synced_at": "2026-09-16T23:19:36.388Z", "location_count": 1, "location_summary": "Denver, Colorado", "locations": [ { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01838863" }, { "nct_id": "NCT01703559", "title": "The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Night Vision Complaints", "Decrease in Night Vision", "Disturbance; Vision, Loss" ], "interventions": [ { "name": "Phentolamine Mesylate Ophthalmic Solution 1.0%", "type": "DRUG" }, { "name": "Phentolamine Mesylate Ophthalmic Solution 0.5%", "type": "DRUG" }, { "name": "Phentolamine Mesylate Ophthalmic Solution Vehicle (Placebo)", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Ocuphire Pharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 60, "start_date": "2011-09-09", "completion_date": "2012-04-30", "has_results": false, "last_update_posted_date": "2019-08-01", "last_synced_at": "2026-09-16T23:19:36.388Z", "location_count": 1, "location_summary": "Phoenix, Arizona", "locations": [ { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01703559" } ] }